SCHEMBL23217906

SCHEMBL23217906

Cc1cccc(-c2nc(C=O)[nH]c2-c2ccc3ncc(OCCN)nc3c2)n1

nearest known ligand 0.46

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
TGFBR1 P36897 20/20 0.46
MTOR P42345 1/20 0.39
MAPK14 Q16539 7/20 0.39
KDR P35968 2/20 0.39
RIPK2 O43353 1/20 0.39
ACVR1B P36896 1/20 0.39
PRKD1 Q15139 2/20 0.34
PDGFRA P16234 1/20 0.34
FLT1 P17948 1/20 0.34
FLT4 P35916 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24164432 0.85 TGFBR1 (0.47) TGFBR1MTORMAPK14KDRRIPK2
SCHEMBL23217899 0.85 TGFBR1 (0.56) TGFBR1MTORMAPK14KDRRIPK2
SCHEMBL23217959 0.83 TGFBR1 (0.41) TGFBR1MTORMAPK14KDRRIPK2
SCHEMBL24164469 0.81 TGFBR1 (0.44) TGFBR1MAPK14KDRRIPK2ACVR1B
SCHEMBL24164816 0.81 TGFBR1 (0.44) TGFBR1MAPK14KDRRIPK2ACVR1B
SCHEMBL23217935 0.80 TGFBR1 (0.43) TGFBR1MAPK14KDRRIPK2ACVR1B
SCHEMBL23217908 0.80 TGFBR1 (0.43) TGFBR1MAPK14KDRRIPK2ACVR1B
SCHEMBL24164888 0.79 TGFBR1 (0.48) TGFBR1MTORMAPK14KDRRIPK2
SCHEMBL24164492 0.79 TGFBR1 (0.51) TGFBR1MAPK14PRKD1
SCHEMBL24164351 0.79 TGFBR1 (0.48) TGFBR1MAPK14PRKD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022006340-A1 ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF SILVERBACK THERAPEUTICS, INC. (US) 2022-01-06 WO disclosed
WO-2022006340-A1 ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF SILVERBACK THERAPEUTICS, INC. (US) 2022-01-06 WO disclosed
WO-2021072330-A1 GALNAC-TGFBR1 INHIBITOR CONJUGATES FOR THE TREATMENT OF LIVER DISEASES SILVERBACK THERAPEUTICS, INC. (US) 2021-04-15 WO disclosed